RNA-Driven Chromatin Shredding Targets Cancer Mutations
Researchers engineered an RNA-guided CRISPR-Cas12a2 nuclease to recognize cancer-specific transcripts and trigger transcript-activated chromatin shredding, leading to DNA damage responses and selective death of cancer cells in experimental systems, offering a potential precision approach to targeting undruggable mutations such as p53.








